NPPB and coronary artery disorder: Additionally, the OPTIMA trial (a prospective multicenter study enrolling patients with PAH, including PAH-CHD) demonstrated that initial double combination therapy with macitentan and tadalafil showed a significant improvement in cardiopulmonary hemodynamics, functional class, NT-proBNP, and risk profile in newly diagnosed patients, from baseline to week 16.